Quick Facts

• Primary Use: Treatment of major depressive episodes in adults.
• Additional Function: May help with normalization of sleep patterns often associated with the condition.
• Relapse Prevention: Used to assist in the prevention of recurrence of depressive symptoms.

---

Valdoxan is a prescription medication authorized for the management of major depressive episodes in adult patients. It is utilized in this therapeutic domain to help address and mitigate symptoms associated with the condition, which may include persistent low mood, changes in sleep and appetite, and loss of interest in activities.

The therapeutic intent of Valdoxan also extends to the long-term support of remission. When a satisfactory response is achieved, continuation of the treatment is indicated to assist in preventing the recurrence of major depressive episodes.

In addition to addressing the core symptoms of the condition, the use of Valdoxan may be associated with an improvement in sleep disturbances that frequently accompany depressive episodes.

Regulatory References

1. EMA therapeutic overview

Valdoxan is officially indicated for the treatment of major depressive episodes in adults.

Contraindicated Populations

Use of Valdoxan is absolutely prohibited in several patient groups, as defined in regulatory labeling:

• Patients with hepatic impairment (such as active liver disease or cirrhosis).
• Patients with liver transaminases (ALT/AST) that are elevated more than three times the upper limit of normal (3x ULN) prior to starting treatment.
• Patients with known hypersensitivity to the active substance, agomelatine, or any excipients.
• Patients concurrently taking potent CYP1A2 inhibitors (e.g., fluvoxamine or ciprofloxacin).

Age-Related and Condition-Specific Restrictions

Population Group	Official Regulatory Status
Children & Adolescents (< 18 years)	Not recommended; safety and efficacy not established.
Older Adults ( ge 75 years)	Should not be used; no effect is documented in this age group.
Elderly with Dementia	Should not be used; safety and efficacy not established.
Pregnancy	Preferable to avoid use as a precautionary measure.
Breastfeeding	Should be discontinued if treatment is necessary.

Use also requires caution in patients with a history of mania/hypomania or with severe or moderate renal impairment. The medicine is restricted for patients with rare hereditary issues like galactose intolerance due to the lactose excipient.

Interactions with other medicines and products

Valdoxan (agomelatine) is primarily broken down in the liver by the enzyme Cytochrome P450 1A2 (CYP1A2), with minor involvement from CYP2C9 and CYP2C19. Interactions with other medicines are governed by how those medicines affect these enzymes.

Co-administration with potent CYP1A2 inhibitors is contraindicated. These medicines, such as fluvoxamine and ciprofloxacin, prevent the breakdown of Valdoxan, leading to a significant increase in its levels in the body.

Other Clinically Relevant Interactions

Product Category	Interaction Mechanism	Official Regulatory Stance
Moderate CYP1A2 Inhibitors (e.g., propranolol, oestrogens)	May increase Valdoxan exposure	Use with caution
CYP1A2 Inducers (e.g., rifampicin, heavy smoking)	Decreases Valdoxan exposure	Use with caution, monitoring may be required
Alcohol (Ethanol)	Risk of additive hepatic injury and potentially enhanced central nervous system effects	Avoid excessive intake
Medicines Associated with Hepatic Injury Risk	Increased potential risk to the liver	Exercise caution

Valdoxan does not inhibit or induce other major CYP450 enzymes and is not expected to affect the concentration of most other medicines.

How Valdoxan Works

Valdoxan (agomelatine) operates via a dual-mechanism of action targeting key neurobiological pathways to adjust signaling and influence physiological processes.

---

Modulation of Melatonergic Receptors

Agomelatine acts as an agonist at the central MT1 and MT2 melatonergic receptors. This activity engages mechanisms that affect the timing of sleep-wake cycles and influence the structure of sleep phases. By stimulating these receptors, the drug modulates signaling relevant to physiological rhythmicity.

---

Serotonergic Pathway Adjustment

Additionally, the drug functions as a neutral antagonist at the 5-HT2C serotonin receptors. This engagement modulates the activity of the 5-HT2C receptor-mediated pathway. Blockade of 5-HT2C receptors initiates a mechanistic cascade that disinhibits the release of the neurotransmitters noradrenaline and dopamine specifically in the frontal cortex. This selective increase in monoamine levels alters the signaling environment in the frontal cortex.

How to Use Valdoxan: Administration Guidelines

Valdoxan (Agomelatine) is administered as a film-coated tablet for oral use once daily. The instructions define the dosing, timing, and monitoring procedures.

Dosing and Schedule

The standard starting dose for adults is 25 mg taken once daily. The maximum recommended dose is 50 mg once daily. The tablet must be taken in the evening, at bedtime, and can be consumed with or without food.

A dose increase from 25 mg to 50 mg may be considered after a minimum of two weeks if the therapeutic response is inadequate. If a dose is missed, take the next dose at the usual time; do not take a double dose to compensate.

Procedural Preconditions and Duration

The administration protocol requires specific procedural preconditions tied to laboratory monitoring. Liver function tests (LFTs) must be performed before starting treatment and before any dose increase to 50 mg.

Treatment should be continued for at least six months after the initial response. No dosage tapering is required when treatment is discontinued, simplifying the process of stopping the medicine.

Population Use Restrictions

Use is contraindicated in patients with hepatic impairment. For older adults, while no dose adjustment is specified for those under 75 years, the medicine is not recommended for patients aged 75 years and over. Caution is advised for use in patients with moderate to severe renal impairment.

Valdoxan: Recent Clinical Evidence

Valdoxan (agomelatine) is a medication authorized for the treatment of major depressive episodes in adults in several international regions. Clinical research has primarily investigated its effects in placebo-controlled and active-comparator trials, focusing on changes in depressive symptoms and measures of quality of life.

Clinical Efficacy Studies

Meta-analyses and randomized controlled trials have examined the compound's effect compared to placebo using scales like the Hamilton Depression Rating Scale (HDRS).

• Comparison to Placebo: In short-term acute treatment studies, agomelatine showed a statistically significant advantage over placebo in reducing depressive symptoms. Some analyses suggest this magnitude of effect, while statistically significant, may be small in absolute clinical terms.
• Comparison to Other Antidepressants: Trials comparing agomelatine to standard antidepressants, such as SSRIs, generally reported equivalent efficacy in the acute phase treatment of major depressive disorder.
• Specific Symptom Areas: Research indicates that the compound's action on the circadian system may be associated with reported improvements in sleep quality and the re-establishment of the sleep-wake cycle in some participants.

Safety and Tolerability Context

The safety profile of agomelatine has been evaluated across various clinical programs.

Safety Finding (Context)	Description in Trials
Liver Function	Trials noted a low incidence of transient elevations in liver aminotransferases in some participants.
Acceptability	Across comparative studies, the compound was generally described as well-tolerated, with some reviews suggesting better acceptability than comparator treatments.

Research continues to monitor the long-term safety profile of the compound, particularly concerning liver function.

Key Studies & References

1. Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials
2. EMA confirms positive benefit-risk for antidepressant Valdoxan/Thymanax (agomelatine) (2014 Safety Review)

Common questions about Valdoxan (FAQ)

Q: How is Valdoxan different from standard antidepressants?

A: Official information states that Valdoxan is classified as a melatonergic antidepressant, which sets it apart from many standard treatments like SSRIs. It works by targeting specific melatonin receptors (MT1 and MT2) and blocking a specific serotonin receptor (5-HT2C). This dual mechanism is noted for its ability to influence the body’s circadian rhythms, or internal clock.

Q: Are there any food or drink restrictions when taking Valdoxan?

A: The official prescribing information indicates that you can take the tablet with or without food. However, official documentation states that excessive consumption of alcohol should be avoided during treatment. This is because alcohol may increase the risk of potential liver injury associated with the medicine.

Q: Is Valdoxan associated with withdrawal symptoms?

A: Official documents state that discontinuation symptoms have been reported when patients stop treatment. These effects, which may include dizziness, sleep disturbances, anxiety, or nausea, are generally described as mild to moderate and tend to disappear spontaneously within a few days.

Q: What does the research say about Valdoxan for long-term use?

A: Research evidence suggests that the drug’s antidepressant effects are maintained over the long term. Studies indicate that its efficacy is sustained and offers protection against the recurrence of depression (relapse) for periods up to 10 months.

Q: Is Valdoxan described as having a different side effect profile compared to older antidepressants?

A: Clinical data summarized in official reviews suggests that this medicine may be associated with a different overall side effect profile. This difference is suggested to be associated with a lower reported incidence of certain side effects, such as sexual dysfunction, when compared to some other types of antidepressants.

Q: What information is available about drug-drug interactions with other mental health medications?

A: Official product information clearly states that Valdoxan is contraindicated (absolutely prohibited) for use with potent CYP1A2 inhibitors. This class of medicine includes the antidepressant fluvoxamine and is expected to cause a marked increase in Valdoxan levels in the body.

Q: How is Valdoxan an agonist and an antagonist at the same time?

A: The medicine has a dual mechanism of action, meaning it works on two different types of brain receptors simultaneously. It acts as an agonist (a stimulator) on the MT1 and MT2 melatonin receptors, while it acts as an antagonist (a blocker) on the 5-HT2C serotonin receptors.

Q: Does Valdoxan interact with over-the-counter pain relievers?

A: The official safety profile advises caution for patients who are taking other medicines known to cause potential hepatic injury (liver damage). Patients are generally advised to inform their healthcare provider of all over-the-counter medicines and supplements they are using.

Q: How long does it typically take for Valdoxan to start working?

A: Official product information indicates that the onset of the antidepressant effect has been observed in clinical trials within one to two weeks after treatment begins.

Q: Is Valdoxan used for anxiety as well as depression?

A: The medication’s sole approved indication is for the treatment of major depressive episodes in adults. However, official clinical studies have reported an improvement in symptoms of both psychic and somatic anxiety associated with depression.

Q: Is Valdoxan available in the United States?

A: According to the US regulatory status, agomelatine (Valdoxan) has not been approved for clinical use by the Food and Drug Administration (FDA).

Q: Is Valdoxan known to affect sex drive?

A: Clinical data summarized in regulatory reviews suggests the drug may be associated with a different sexual side effect profile compared to some other antidepressant classes. However, libido disorders and sexual dysfunction are listed as uncommon side effects in official documents.

Q: Do common medications for high blood pressure interact with Valdoxan?

A: Official documents advise caution when co-administering Valdoxan with moderate CYP1A2 inhibitors. This class of medicines includes the drug propranolol, which is often prescribed for high blood pressure, as it may increase the amount of Valdoxan in the body.

Q: Does Valdoxan have a potential for misuse or dependence?

A: Official regulatory context supports a low potential for physical dependence. The product information indicates that discontinuation does not require mandatory dosage tapering. Furthermore, the drug is not listed as a scheduled controlled substance in the United States.

Q: Can Valdoxan affect my ability to drive or operate machinery?

A: Official product information contains a warning regarding the potential impact on a person's ability to drive or operate machinery. This is because common side effects listed include dizziness and somnolence (sleepiness).

Q: Is Valdoxan a controlled substance in certain countries?

A: According to international controlled substance listings, agomelatine is not listed as a scheduled controlled substance under the US Controlled Substances Act.

Q: Does Valdoxan cause changes in blood sugar levels?

A: Official product information mentions diabetes as a risk factor for hepatic injury that requires careful consideration before treatment. The regulatory documents indicate that patients with risk factors should be monitored closely.

Q: Is Valdoxan recommended for people with severe depression?

A: The product is indicated for the treatment of major depressive episodes in adults. Clinical evidence supports the use of this medicine in patients whose major depressive episode is classified as moderate to severe.

How to Store and Dispose of Valdoxan (Agomelatine)

The official regulatory profile establishes specific conditions for storing and handling Valdoxan tablets.

---

Storage Requirements

Valdoxan does not require any special storage conditions to maintain its 3-year shelf life. The tablets should remain in their original Aluminium/PVC blister packs until use. For safety, the medicine must be kept out of the sight and reach of children.

Classification	Requirement
Temperature	No special conditions required.
Child Safety	Keep out of the sight and reach of children.
Shelf Life	3 years in original packaging.

Disposal

Disposal instructions state that any unused or expired medicinal product or waste material must be discarded in accordance with local requirements for pharmaceutical waste. No special environmental restrictions are explicitly noted in the product labeling; local regulations govern the final disposal.